NYSEAMERICAN:TRXC - TransEnterix Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$6.45 -0.07 (-1.07 %)
(As of 09/20/2018 02:20 PM ET)
Previous Close$6.68
Today's Range$6.09 - $6.75
52-Week Range$1.15 - $6.70
Volume382,185 shs
Average Volume4.69 million shs
Market Capitalization$354.65 million
P/E RatioN/A
Dividend YieldN/A
Beta2.12
TransEnterix logoTransEnterix, Inc., a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery. The company offers Senhance System, a multi-port robotic surgery system, which allows up to four arms to control robotic instruments and a camera in Europe. It also develops SurgiBot System, a single-port system robotically enhanced laparoscopic surgical platform.. TransEnterix, Inc. is headquartered in Morrisville, North Carolina.

Receive TRXC News and Ratings via Email

Sign-up to receive the latest news and ratings for TRXC and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Medical Instruments & Supplies
Sub-IndustryN/A
SectorMedical
SymbolNYSEAMERICAN:TRXC
CUSIPN/A
Phone+1-919-7658400

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-21,045.36%
Return on Equity-137.69%
Return on Assets-83.60%

Miscellaneous

EmployeesN/A
Outstanding Shares208,970,000
Market Cap$354.65 million

TransEnterix (NYSEAMERICAN:TRXC) Frequently Asked Questions

What is TransEnterix's stock symbol?

TransEnterix trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "TRXC."

How were TransEnterix's earnings last quarter?

TransEnterix, Inc. (NYSEAMERICAN:TRXC) released its quarterly earnings data on Tuesday, August, 7th. The medical instruments supplier reported ($0.06) earnings per share for the quarter, hitting the Thomson Reuters' consensus estimate of ($0.06). The medical instruments supplier had revenue of $6.39 million for the quarter, compared to the consensus estimate of $6.20 million. TransEnterix had a negative net margin of 21,045.36% and a negative return on equity of 137.69%. View TransEnterix's Earnings History.

When is TransEnterix's next earnings date?

TransEnterix is scheduled to release their next quarterly earnings announcement on Thursday, November, 8th 2018. View Earnings Estimates for TransEnterix.

What price target have analysts set for TRXC?

3 brokers have issued 1-year price targets for TransEnterix's stock. Their forecasts range from $4.00 to $5.50. On average, they expect TransEnterix's stock price to reach $4.75 in the next twelve months. This suggests that the stock has a possible downside of 25.3%. View Analyst Price Targets for TransEnterix.

What is the consensus analysts' recommendation for TransEnterix?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TransEnterix in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for TransEnterix.

Are investors shorting TransEnterix?

TransEnterix saw a decrease in short interest during the month of August. As of August 31st, there was short interest totalling 31,383,304 shares, a decrease of 4.0% from the August 15th total of 32,705,941 shares. Based on an average daily trading volume, of 5,239,459 shares, the short-interest ratio is currently 6.0 days. Approximately 19.2% of the company's shares are sold short. View TransEnterix's Current Options Chain.

Who are some of TransEnterix's key competitors?

Who are TransEnterix's key executives?

TransEnterix's management team includes the folowing people:
  • Mr. Todd M. Pope, CEO, Pres & Director (Age 53)
  • Mr. Joseph P. Slattery, Exec. VP, CFO & Principal Accounting Officer (Age 53)
  • Mr. Anthony Fernando, COO, CTO & Exec. VP (Age 46)
  • Mr. Joshua B. Weingard, Chief Legal Officer & Sec. (Age 45)
  • Dr. Stephanie M. Fitts Ph.D., VP of RA/QA, Clinical and Compliance (Age 52)

Has TransEnterix been receiving favorable news coverage?

Media headlines about TRXC stock have been trending somewhat positive on Thursday, according to Accern Sentiment Analysis. Accern ranks the sentiment of news coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. TransEnterix earned a media and rumor sentiment score of 0.18 on Accern's scale. They also assigned media headlines about the medical instruments supplier an impact score of 46.57 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near term. View Recent Headlines for TransEnterix.

Who are TransEnterix's major shareholders?

TransEnterix's stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (4.89%), Global X Management Co LLC (1.23%), Eagle Asset Management Inc. (0.39%), Northern Trust Corp (0.29%), Bank of New York Mellon Corp (0.25%) and Bank of New York Mellon Corp (0.24%). Company insiders that own TransEnterix stock include Anthony C J Fernando, Joseph P Slattery, Richard C Pfenniger Jr, SPA Sofar, Todd Pope and Willam N Kelley. View Institutional Ownership Trends for TransEnterix.

Which major investors are selling TransEnterix stock?

TRXC stock was sold by a variety of institutional investors in the last quarter, including Bank of America Corp DE. Company insiders that have sold TransEnterix company stock in the last year include Anthony C J Fernando, Joseph P Slattery and Todd Pope. View Insider Buying and Selling for TransEnterix.

Which major investors are buying TransEnterix stock?

TRXC stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Global X Management Co LLC, Eagle Asset Management Inc., Bank of New York Mellon Corp, Bank of New York Mellon Corp, Northern Trust Corp, Schwab Charles Investment Management Inc. and EAM Global Investors LLC. Company insiders that have bought TransEnterix stock in the last two years include Richard C Pfenniger Jr, SPA Sofar and Willam N Kelley. View Insider Buying and Selling for TransEnterix.

How do I buy shares of TransEnterix?

Shares of TRXC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is TransEnterix's stock price today?

One share of TRXC stock can currently be purchased for approximately $6.36.

How big of a company is TransEnterix?

TransEnterix has a market capitalization of $354.65 million.

How can I contact TransEnterix?

TransEnterix's mailing address is 635 Davis Dr Ste 300, MORRISVILLE, NC 27560-7199, United States. The medical instruments supplier can be reached via phone at +1-919-7658400.


MarketBeat Community Rating for TransEnterix (NYSEAMERICAN TRXC)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  255 (Vote Outperform)
Underperform Votes:  288 (Vote Underperform)
Total Votes:  543
MarketBeat's community ratings are surveys of what our community members think about TransEnterix and other stocks. Vote "Outperform" if you believe TRXC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TRXC will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel